Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235885 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 445
- Enrollment target
NCT00235885 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 445 participants.
The verdict
NCT00235885, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 445 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety and clinical efficacy of adalimumab in active psoriatic arthritis (PsA) subjects when adalimumab is added to insufficient standard therapy including patients that have failed other TNF therapies
Interventions
- DRUG adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 445 participants |
| Start Date | 2005-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00235885
The ClinicalTrials.gov registry entry for NCT00235885 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 445 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which adalimumab is the first listed.
NCT00235885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00235885 about?
NCT00235885 is a clinical study titled "Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)". The purpose of the study is to assess the safety and clinical efficacy of adalimumab in active psoriatic arthritis (PsA) subjects when adalimumab is added to insufficient standard therapy including patients that have failed other TNF therapies
What is the current status of trial NCT00235885?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 445 participants. The study started on 2005-07.
What interventions are being tested in trial NCT00235885?
The interventions under investigation include: adalimumab (DRUG).
Who is sponsoring clinical trial NCT00235885?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.